These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. Yoshisue H; Kirkham-Brown J; Healy E; Holgate ST; Sampson AP; Davies DE J Allergy Clin Immunol; 2007 Jan; 119(1):132-40. PubMed ID: 17208594 [TBL] [Abstract][Full Text] [Related]
26. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Bronsky EA; Kemp JP; Zhang J; Guerreiro D; Reiss TF Clin Pharmacol Ther; 1997 Nov; 62(5):556-61. PubMed ID: 9390112 [TBL] [Abstract][Full Text] [Related]
27. The cysteinyl-leukotriene D4 induces cytosolic Ca2+ elevation and contraction of the human detrusor muscle. Bouchelouche K; Andersen L; Nordling J; Horn T; Bouchelouche P J Urol; 2003 Aug; 170(2 Pt 1):638-44. PubMed ID: 12853847 [TBL] [Abstract][Full Text] [Related]
28. Cysteinyl leukotriene antagonism inhibits bronchoconstriction in response to hypertonic saline inhalation in asthma. Kazani S; Sadeh J; Bunga S; Wechsler ME; Israel E Respir Med; 2011 May; 105(5):667-73. PubMed ID: 21169002 [TBL] [Abstract][Full Text] [Related]
29. Reproducibility of leukotriene D4 inhalation challenge in asthmatics. Effect of a novel leukotriene D4/E4-antagonist (SR 2640) on leukotriene D4-induced bronchoconstriction. Frølund L; Madsen F; Nielsen J Allergy; 1991 Jul; 46(5):355-61. PubMed ID: 1928658 [TBL] [Abstract][Full Text] [Related]
30. Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial. Ramsay CF; Sullivan P; Gizycki M; Wang D; Swern AS; Barnes NC; Reiss TF; Jeffery PK Respir Med; 2009 Jul; 103(7):995-1003. PubMed ID: 19249198 [TBL] [Abstract][Full Text] [Related]
31. Comparison study between the mechanisms of allergic asthma amelioration by a cysteinyl-leukotriene type 1 receptor antagonist montelukast and methylprednisolone. Murai A; Abe M; Hayashi Y; Sakata N; Katsuragi T; Tanaka K J Pharmacol Exp Ther; 2005 Feb; 312(2):432-40. PubMed ID: 15470084 [TBL] [Abstract][Full Text] [Related]
32. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Shimbori C; Shiota N; Okunishi H Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736 [TBL] [Abstract][Full Text] [Related]
33. The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. Gómez FP; Iglesia R; Roca J; Barberà JA; Chung KF; Rodriguez-Roisin R Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1559-64. PubMed ID: 9603138 [TBL] [Abstract][Full Text] [Related]
34. The ACh-induced contraction in rat aortas is mediated by the Cys Lt1 receptor via intracellular calcium mobilization in smooth muscle cells. Mazzetti L; Franchi-Micheli S; Nistri S; Quattrone S; Simone R; Ciuffi M; Zilletti L; Failli P Br J Pharmacol; 2003 Feb; 138(4):707-15. PubMed ID: 12598425 [TBL] [Abstract][Full Text] [Related]
35. [The role of leukotrienes in inflammation and leukotriene inhibitors]. Kupczyk M; Kuna P Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480 [TBL] [Abstract][Full Text] [Related]
36. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Micheletto C; Tognella S; Visconti M; Pomari C; Trevisan F; Dal Negro RW Allergy; 2004 Mar; 59(3):289-94. PubMed ID: 14982510 [TBL] [Abstract][Full Text] [Related]
37. Relation between bronchial responsiveness to inhaled leukotriene D4 and markers of leukotriene biosynthesis. Gyllfors P; Kumlin M; Dahlén SE; Gaber F; Ehrs PO; Dahlén B Thorax; 2005 Nov; 60(11):902-8. PubMed ID: 16055619 [TBL] [Abstract][Full Text] [Related]
38. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Dahlén B; Zetterström O; Björck T; Dahlén SE Eur Respir J; 1994 Feb; 7(2):324-31. PubMed ID: 8162986 [TBL] [Abstract][Full Text] [Related]
39. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Dahlén B; Nizankowska E; Szczeklik A; Zetterström O; Bochenek G; Kumlin M; Mastalerz L; Pinis G; Swanson LJ; Boodhoo TI; Wright S; Dubé LM; Dahlén SE Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1187-94. PubMed ID: 9563738 [TBL] [Abstract][Full Text] [Related]
40. Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. Parameswaran K; Liang H; Fanat A; Watson R; Snider DP; O'Byrne PM J Allergy Clin Immunol; 2004 Jul; 114(1):73-9. PubMed ID: 15241347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]